Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

PhRMA defends Gilead's pricey Sovaldi as docs look forward to more hep C choices

11.04.2014 / Fierce Pharma

Ever since Gilead's $1,000-per-day hepatitis C pill Sovaldi stormed the market late last year, the company has been under pressure from legislators, insurers, and patient advocacy groups to lower its price. Now, doctors are weighing in on the debate.

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: